Health Care • Biotechnology: Pharmaceutical Preparations
$1.22 ▼ -0.02
(-1.61%)
MKT CAP: $11.5M • VOL: 111.9K
52W L $1 52W H $5
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CLRB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.0M | -$51.8M | -$39.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$21.8M | -$44.6M | -$38.0M |
| EBITDA (Normalized) | -$23.0M | -$51.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.1M | -$47.6M | -$32.4M |
| Capital Expenditures (CapEx) | $5.9K | $104.2K | — |
| Free Cash Flow (FCF) | -$23.1M | -$47.7M | -$32.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $13.2M | $23.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.5M | $14.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLRB.